Market Place
Sourcing Support
Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate
08 May 2023 //
BUSINESSWIRE
New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114
24 Apr 2023 //
BUSINESSWIRE
Trefoil Therapeutics Announces TTHX1114 Data Presentations at (ARVO)
17 Apr 2023 //
BUSINESSWIRE
Trefoil begins subject dosing in corneal epithelial defects therapy trial
19 Jan 2023 //
CLINICAL TRIALS ARENA
Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114
18 Jan 2023 //
BUSINESSWIRE
Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data
29 Sep 2022 //
BUSINESSWIRE
Trefoil Announces Third Tranche of $28M Series A Financing
01 Dec 2021 //
BUSINESSWIRE
Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial
09 Feb 2021 //
BUSINESSWIRE
Trefoil Begins Second Phase 2 “STORM” Clinical Trial Regenerative Treatment
09 Feb 2021 //
BUSINESSWIRE
Trefoil to Present Update on Regenerative Treatments for Corneal Diseases
02 Nov 2020 //
BUSINESSWIRE
Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment
19 Aug 2020 //
BUSINESSAWIRE
Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment
19 Aug 2020 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.